Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp (NYSE:PLX)

Protalix BioTherapeutics is advancing a rare-disease pipeline with its plant-cell platform, led by Elfabrio and compelling valuation. See why PLX stock is a buy.